Clinical review report: Eliglustat (Cerdelga) (Sanofi Genzyme) : indication: Gaucher disease type 1
The objective of this report was to perform a systematic review of the beneficial and harmful effects of eliglustat 84 mg capsules for the long-term treatment of adults with Gaucher disease type 1 (GD1) who are cytochrome P450 2D6 (CYP2D6) poor metabolizers, intermediate metabolizers, or extensive m...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, August 2017
|
Edition: | Version 1.0 |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of eliglustat 84 mg capsules for the long-term treatment of adults with Gaucher disease type 1 (GD1) who are cytochrome P450 2D6 (CYP2D6) poor metabolizers, intermediate metabolizers, or extensive metabolizers |
---|---|
Physical Description: | 1 PDF file (93 pages) illustrations |